Avelumab
Programmed Death Ligand-1 Blocker — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: bavencio, MSB0010682, MSB0010718C
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Avelumab is a drug in the Programmed Death Ligand-1 Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Programmed Death Ligand-1 Antagonists and Programmed Death Ligand-1-directed Antibody Interactions. DrugCentral lists 1 molecular target, including CD274. Recorded indications include Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy, Merkel cell carcinoma and Renal cell carcinoma.
- Drug class: Programmed Death Ligand-1 Blocker.
- Mechanism of action: Programmed Death Ligand-1 Antagonists; Programmed Death Ligand-1-directed Antibody Interactions.
- Molecular targets: CD274 (1 listed in DrugCentral).
- Indications: Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy, Merkel cell carcinoma and Renal cell carcinoma.
- ATC code: L01FF04 (PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (3)
- Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy
- Merkel cell carcinoma
- Renal cell carcinoma
Mechanism & targets
| Mechanism of action (MoA) | Programmed Death Ligand-1 Antagonists; Programmed Death Ligand-1-directed Antibody Interactions |
|---|---|
| Established pharmacologic class | Programmed Death Ligand-1 Blocker |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Programmed cell death 1 ligand 1 | CD274 | other | — |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2017-09-27 | PMDA | — | Merck Serono Co., Ltd. | Yes |
| 2017-09-18 | EMA | — | Merck Europe B.V. | Yes |
| 2017-03-23 | FDA | — | EMD SERONO INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FF04 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: CD274
- FDA label: CD274
- HCSC label: CD274
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Disease progression | 726.1 |
| Death | 289.9 |
| Neoplasm progression | 283.2 |
| Myocarditis | 161.3 |
| Hypothyroidism | 159.1 |
| Interstitial lung disease | 152.4 |
| Adrenal insufficiency | 125.7 |
| Pneumonitis | 117.5 |
| Infusion related reaction | 109.8 |
| Skin toxicity | 109.1 |
| Myositis | 105.0 |
| Chills | 99.5 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1537032-82-8 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Avelumab used for?
DrugCentral lists the following indications for Avelumab: Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy, Merkel cell carcinoma and Renal cell carcinoma.
How does Avelumab work?
Avelumab is classified as Programmed Death Ligand-1 Antagonists and Programmed Death Ligand-1-directed Antibody Interactions; its molecular targets in DrugCentral include CD274.
When was Avelumab first approved?
Avelumab was first approved by the FDA in 2017.
What drug class does Avelumab belong to?
Avelumab is in the Programmed Death Ligand-1 Blocker class.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5221 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3833373 — compound record and bioactivity
- DrugBank DB11945 — drug record
- FDA UNII KXG2PJ551I — substance identity
- DailyMed: FDA labels for Avelumab — current prescribing information (label search)
- UniProt Q9NZQ7 (CD274) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.